Home › Paraganglioma › Michigan
Paraganglioma clinical trials in Michigan
3 studies for Paraganglioma are looking for participants at sites in Michigan.
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- University of Michigan ( Site 0126), Ann Arbor
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT04924075Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
- U of Michigan, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT07282587Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health, Grand Rapids
- Michigan Health Professionals, Troy
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated May 14, 2026 · NCT05636618From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.